Life Sciences Tools and Services

SMOC

SMOC released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 99.92 M, actual EPS CNY 0.01

SMOC to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

SMOC FY2025 Annual Earnings Release on April 27, 2026 During-Market (BJT)

SMOC released FY2025 Annual Earnings on February 27 During-Market (BJT), actual revenue CNY 421.02 M, actual EPS CNY 0.42

SMOC released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue CNY 118.32 M, actual EPS CNY 0.0738

SMOC released FY2025 Q3 earnings on October 29 After-Market BJT, actual revenue CNY 106.94 M, actual EPS CNY 0.1099

SMOC released FY2025 9 Months Earnings on October 29 After-Market BJT, actual revenue CNY 302.7 M, actual EPS CNY 0.4121

SMOC to Release FY2025 Q3 Earnings on October 30 After-Market (BJT)

SMOC released FY2025 Semi-Annual Earnings on August 28 After-Market BJT, Actual Revenue: CNY 195.76 M, Actual EPS: CNY 0.23

SMOC released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue CNY 107.37 M, actual EPS CNY 0.3121

SMOC to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Nanomodel Biology's ESG Rating Results Announced

SMOC released FY2025 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 88.4 M, actual EPS CNY -0.01

SMOC to Release FY2025 Q1 Earnings Report on April 29 After-Market BJT

SMOC to release FY2024 earnings on April 29 After-Market (BJT), forecast revenue CNY 669 M, EPS CNY 1.91

Shareholder of Nanmo Biology Reduces Shares by 1.4269 Million, Terminates Reduction Plan Early

SMOC released FY2024 Q4 earnings on February 27 After-Market BJT, actual revenue CNY 116.39 M, actual EPS CNY 0.2239

SMOC released FY2024 annual earnings on February 27 After-Market BJT, actual revenue CNY 381.24 M (forecast CNY 669 M), actual EPS CNY 0.08 (forecast CNY 1.91)

Nanmo Biology releases Q3 2024 financial report

SMOC released FY2024 9 Months Earnings on October 30 After-Market (BJT), with actual revenue of 264.85 M CNY and EPS of -0.201 CNY

688265

SMOC announced that its operating income in the first half of 2025 was 196 million yuan, a year-on-year increase of 10.69%. The net profit was 18.1674 million yuan, compared to a loss of 9.1436 million yuan in the same period last year

Zhitong

SMOC: Net profit of 18.1674 million yuan in the first half of 2025, year-on-year growth not applicable

688091

002173

688428

09969

300436

Pharmaceutical stocks showed divergence during the session, with Cosunter plunging nearly 10%, while InnoCare Pharma, SMOC, SHANGHAI YIZHONG, and Innovative Medical all saw significant declines

SHANGHAI YIZHONG

Innovative Medical

InnoCare Pharma

INNOCARE

Cosunter

Pharmaceutical stocks show divergence during trading, with Cosunter experiencing a significant drop

SMOC announced that the closing price of the company's stock has deviated by more than 30% over two consecutive trading days, which constitutes an abnormal fluctuation in stock trading. After the company conducted a self-examination and verified with the company's controlling shareholder and actual controller in writing, as of the date of this announcement, there is no significant information that should be disclosed but has not been disclosed. The company's stock price has experienced significant short-term volatility, and investors are advised to pay attention to secondary market trading risks, make prudent decisions, and invest rationally

SMOC: Stock has risen more than 30% for two consecutive days

SMOC announced that HaiRun RongFeng, Kang Jun Ning Yuan, and Zhang Jiang Collective signed a share transfer agreement with HaiWang HeZong to transfer 8.6797 million shares at a price of 27.37 yuan per share. The transfer will be completed on August 12, 2025, with the transfer date set for August 11, 2025. After the transfer, HaiWang HeZong and its concerted parties will hold 14.0228 million shares of the company, accounting for 17.99% of the total share capital. HaiWang HeZong commits not to reduce its holdings of the acquired shares within 12 months

SMOC: Haiwang Hezong acquired 8.6797 million shares of the company

603538

603987

301126

300289

The concept of assisted reproduction has rebounded after hitting the bottom, with SMOC, Leadman, and Mailland rising over 15%. Cosunter, KDL, DAJIAWEIKANG, Zhongsheng Pharmaceutical, and Menovo followed suit

Menovo

DAJIAWEIKANG

Leadman

The concept of assisted reproduction rebounds after hitting the bottom, Leadman rises over 15%

SMOC announced that some shareholders plan to transfer 11.13% of their shares to Haiwang Hezong due to funding needs. HaiRun RongFeng, Kang JunNingYuan, and ZhangJiang Collective will transfer 4.6503 million shares, 2.2474 million shares, and 1.782 million shares respectively at a price of 27.369 yuan per share. After the transfer, Haiwang Hezong will hold 8.6797 million shares, accounting for 11.13% of the total share capital. After the equity change, HaiRun RongFeng and ZhangJiang Collective will no longer hold shares, while Kang JunNingYuan will hold 1.5607 million shares, accounting for 2%

Snibe

Some shareholders of SMOC plan to transfer a total of 11.13% of the company's shares to Haiwang Hezhong

600458

688206

300636

601956

688511

On June 27, a total of 12 listed companies had their restricted shares unlocked, with a total market value of approximately 7.717 billion yuan. The specific situation of the restricted share unlock today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares TMT 600458 Equity Incentive Restricted Circulation 679,800 DONPER GROUP 601956 Equity Incentive Restricted Circulation 3,103,800 SYNERGY 300636 Equity Incentive Restricted Circulation 1,570,000 Shandong Glass Fiber 605006 Equity Incentive Restricted Circulation 330,900 Aoni Electronics 301189 Extended Restricted Lock-up Period Circulation 7,372,000 Biyih Shares 603215 Equity Incentive Restricted Circulation 15,500 Tianwei Electronics 688511 2,595,000 SMOC 688265 28,575,000 Tonglian Precision 688210 5,285,500 PRIMARIUS 688206 625,700 Ankai Micro 688620 39,200 Huafeng Technology 688629 34,574,000

PRIMARIUS

SYNERGY

DONPER GROUP

Sichuan Tianwei Electronics

ANYKA MICROELECTRONICS

BIYI

Huafeng

aoni

Union Precision

Zhitong A-shares lock-up release overview | June 27

688117

000788

300142

688136

The innovative drug sector weakened, with individual stocks showing mixed performance. Sinovac Biotech fell over 13%, Warner Pharmaceuticals dropped over 9%, and Xinlitai declined over 8%. SNSW and Kanghong Pharmaceutical both fell over 7%; PKU HEALTHCARE hit the daily limit up, WALVAX rose over 7%, and Zhifei Biological and SMOC increased over 4%

SNSW

PKU HEALTHCARE

WALVAX

SDKX

KHPG

Salubris

ZHIFEI-BIOL

HWPC

603127

06127

02228

02315

- The FDA's recent roadmap aims to reduce animal testing in drug development, promoting alternatives like organoids and computer simulations.  
- This shift is expected to impact companies reliant on animal models, particularly those involved in non-clinical safety evaluations, as they adapt to new technologies.  
- While the transition may be gradual, the industry is increasingly investing in innovative solutions, indicating a long-term trend towards minimizing animal use in research.

Wallstreetcn

JOINN

XTALPI

BIOCYTOGEN-B

WUXI APPTEC

The shockwave of animal experiments is forcing AI drug development to accelerate its evolution

According to the Zhitong Finance APP, SMOC announced that its shareholder Beijing Kangjun Ningyuan Equity Investment Partnership (Limited Partnership) (referred to as "Kangjun Ningyuan") has reduced its holdings in the company by a total of 1.4269 million shares through centralized bidding and block trading, accounting for 1.83% of the total shares of the company, and has terminated the reduction plan in advance

SMOC shareholder Kang Junningyuan completed the reduction of 1.83% of shares

SMOC(688265.SH)